Nasdaq15d
Supernus Pharmaceuticals Announces FDA Approval for Updated Qelbree Label Including New Pharmacodynamic Data and Lactation Information
Supernus Pharmaceuticals, Inc. announced that the FDA has approved an updated label for Qelbree (viloxazine extended-release capsules ... a multi-dose (600 mg daily for three days) regimen ...
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
Business Insider15d
Supernus announces U.S. FDA approved an update for label for Qelbree
Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to include new pharmacodynamic data in Section 12.2. The ...
Business Insider7d
Supernus announces FDA approval of ONAPGO
Supernus (SUPN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, approved ONAPGO injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine ...
Yahoo Finance6d
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...
Investing15d
FDA approves Qelbree label update for ADHD treatment
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a label update for ...
Yahoo Finance16d
Supernus Pharmaceuticals, Inc. (SUPN)
specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree® (viloxazine extended-release capsules) has been accepted for review by Health Canada.
Nasdaq7d
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, the First Subcutaneous Apomorphine Infusion Device for Parkinson's Disease in the U.S.
Supernus Pharmaceuticals has announced the FDA approval of ONAPGO, the first subcutaneous apomorphine infusion device specifically designed to treat motor fluctuations in adults with advanced ...
Investing7d
Supernus stock surges on FDA approval
Investing.com -- Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) climbed 5.5% Tuesday as the U.S. Food and Drug Administration approved ONAPGO for the treatment of motor fluctuations in adults ...